Colorectal Cancer
Overcoming the critical post-surgical diagnostic gap where early-stage micro-metastases or systemic molecular recurrence are frequently missed by conventional tools.
Home / About
Who we arePlasmaDtect is an innovative biotechnology company at the forefront of non-invasive oncology diagnostics — moving beyond the limitations of traditional tissue-based biopsies.
PlasmaDtect specializes in the development of ultra-sensitive, blood-based diagnostic solutions. Our mission is to close the critical clinical blindspot in cancer monitoring by providing comprehensive tools for early-stage detection and highly accurate Minimal Residual Disease (MRD) surveillance.
By translating complex molecular biology into actionable, high-precision clinical insights, we empower oncologists to optimize therapeutic strategies, monitor treatment responses in real time, and proactively intercept recurrence.
Traditional workflows rely on invasive tissue biopsies that require surgical tumor blocks, entail lengthy turnaround times, and carry significant economic burdens. Standard surveillance tools frequently lack the sensitivity to detect low-abundance residual tumor cells.
Clear, non-invasive detection pathways from a single blood draw — covering critical oncological indications.
Overcoming the critical post-surgical diagnostic gap where early-stage micro-metastases or systemic molecular recurrence are frequently missed by conventional tools.
Eliminating the necessity for highly invasive and repetitive monitoring procedures through definitive, blood-based molecular surveillance.
Supporting global screening efforts with a high-throughput, blood-based diagnostic framework capable of identifying distinct epigenetic variations.
Facilitating early intervention and therapeutic tracking in high-risk populations where early structural detection remains notoriously difficult.
An elite, interdisciplinary group of oncology researchers, geneticists, and global startup strategists.
Explore our leadership